Policy
Jim O’Neill was deputy secretary at the Department of Health and Human Services and also acting director of the CDC after the abrupt ouster of Susan Monarez in August 2025.
FEATURED STORIES
Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are keeping many of the terms of their agreements private.
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates have been fighting to get it back ever since.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The same day that New York Gov. Andrew Cuomo announced the initiation of a clinical trial using blood plasma from patients who have recovered from COVID-19, the U.S. Food and Drug Administration announced wider support for the practice.
PerkinElmer is the 16th company to receive an EUA for COVID-19 testing.
A summary of daily biopharma industry news. Please check out stories that are trending on March 25, 2020.
The ointment had previously been approved for patients ages two and above in 2016.
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
“Using untested drugs without the right evidence could raise false hope and even do more harm than good and cause a shortage of essential drugs that are needed to treat other diseases,” said WHO Director-General Tedros Adhanom Ghebreyesus.
Insys founder John Kapoor is using the coronavirus pandemic as part of his legal defense to remain out of prison while he appeals his January racketeering conviction.
The U.S. Food and Drug Administration issued a Completed Response Letter of Eli Lilly and Company and Boehringer Ingelheim’s Jardiance (empaglifozin) for type 1 diabetes.
A summary of daily biopharma industry news. Please check out stories that are trending on March 23, 2020.
The U.S. Food and Drug Administration has a busy week of possible drug approvals on its calendar. Here’s a look.